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ABSTRACT
Objectives: To estimate the prevalence and
characteristics of frequent nocturnal sweating in
obstructive sleep apnoea (OSA) patients compared with
the general population and evaluate the possible
changes with positive airway pressure (PAP) treatment.
Nocturnal sweating can be very bothersome to the
patient and bed partner.
Design: Case–control and longitudinal cohort study.
Setting: Landspitali—The National University Hospital,
Iceland.
Participants: The Icelandic Sleep Apnea Cohort
consisted of 822 untreated patients with OSA, referred
for treatment with PAP. Of these, 700 patients were
also assessed at a 2-year follow-up. The control group
consisted of 703 randomly selected subjects from the
general population.
Intervention: PAP therapy in the OSA cohort.
Main outcome measures: Subjective reporting of
nocturnal sweating on a frequency scale of 1–5:
(1) never or very seldom, (2) less than once a week,
(3) once to twice a week, (4) 3–5 times a week and
(5) every night or almost every night. Full PAP
treatment was defined objectively as the use for
≥4 h/day and ≥5 days/week.
Results: Frequent nocturnal sweating (≥3× a week)
was reported by 30.6% of male and 33.3% of female
OSA patients compared with 9.3% of men and 12.4%
of women in the general population (p<0.001). This
difference remained significant after adjustment for
demographic factors. Nocturnal sweating was related to
younger age, cardiovascular disease, hypertension,
sleepiness and insomnia symptoms. The prevalence of
frequent nocturnal sweating decreased with full PAP
treatment (from 33.2% to 11.5%, p<0.003 compared
with the change in non-users).
Conclusions: The prevalence of frequent nocturnal
sweating was threefold higher in untreated OSA
patients than in the general population and decreased
to general population levels with successful PAP
therapy. Practitioners should consider the possibility of
OSA in their patients who complain of nocturnal
sweating.
INTRODUCTION
Nocturnal sweating is a symptom commonly
encountered in clinical medicine (reviewed
by1), but has only been evaluated to a limited
ARTICLE SUMMARY
Article focus
▪ Previous studies have suggested a possible rela-
tionship between obstructive sleep apnoea and
frequent nocturnal sweating. However until now,
studies comparing the prevalence of frequent
nocturnal sweating in untreated sleep apnoea
patients compared with the general population
as well as changes with sleep apnoea treatment
have been lacking. Our study focuses on the role
of nocturnal sweating in sleep apnoea.
Key messages
▪ Our study indicates a possible role of frequent
nocturnal sweating as a marker for untreated
sleep apnoea. One-third of adults with sleep
apnoea experience this symptom and they are
three times more likely to report it compared
with adults in the general population. The
symptom is responsive to treatment in the
majority of sleep apnoea patients.
▪ Clinicians should include sleep apnoea in the dif-
ferential diagnosis of patients presenting with a
complaint of nocturnal sweating and further
investigate that possibility.
Strengths and limitations of this study
▪ The strengths of this study include the detailed
assessment of a large number of sleep apnea
patients studied with a two year follow-up and
the comparison with a general population
cohort.
▪ Our study was an observational study, not a ran-
domised controlled trial, which may be consid-
ered a limitation. Other limitations include the
use of subjective measures of sweating and the
smaller number of women with sleep apnea than
men, due to lower prevalence.
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degree. Nocturnal sweating can be very bothersome to
the patient and the bed partner, often causing the
drenching of bed clothes, and is associated with a
reduced quality of life.2–4 However, only a minority of
patients report this symptom to their physician.3 4 The
possible causes of nocturnal sweating include, but are not
limited to, malignancy, infections, endocrine and neuro-
logical disorders, menopause, gastroesophageal reﬂux
(GER), medications (mainly antidepressants and antipyre-
tics), substance abuse, panic attacks as well as sleep disor-
ders, such as obstructive sleep apnoea (OSA) and
insomnia (refs. 4–6 and reviewed by the authors of refs. 1 7–
9). Other causes can be as simple as an overheated room
or too thick bed clothes (reviewed by Smetana1).
Nocturnal sweating has been associated with increased
daytime tiredness and sleep problems in a general popula-
tion cohort3 4 as well as in patients referred to a sleep
laboratory.10 A recent review article by Mold et al9 stated
that much is still unknown about the causes, evaluation
and management of nocturnal sweating.
OSA is characterised by the repetitive closure of the
pharyngeal airway during sleep that is associated with
oxygen desaturations and/or arousals. Patients with OSA
have disturbed sleep and excessive daytime sleepiness.11 It
has been reported that half of OSA patients report noctur-
nal sweating, usually around the neck and upper body
area.12 A recently published study of 98 men with
untreated OSA found that 34% reported nocturnal sweat-
ing which was reduced to 12% with positive airway pres-
sure (PAP) treatment.13 Those OSA patients who still
reported sweating on PAP treatment were younger and
had higher OSA severity. However, in another study, sweat-
ing complaints were not related to the OSA severity.10
A study by our group14 found that untreated OSA patients
with a higher electrodermal activity index, an objective
measurement of sweating, could reliably estimate the self-
report of sweating. These patients also had higher blood
pressure and both sweating and blood pressure decreased
objectively with PAP treatment.14 However, larger studies
comparing the prevalence of nocturnal sweating in OSA
patients before and after treatment, as well as compari-
sons with randomly selected subjects from the general
population, are needed to conﬁrm the association
between nocturnal sweating and OSA.
The aim of this study was to evaluate the prevalence
and characteristics of nocturnal sweating in patients
diagnosed with OSA, both before and following PAP
treatment, compared with the general population. The
primary a priori hypothesis for this study was that OSA
patients have an increased prevalence of nocturnal
sweating that normalises with PAP treatment.
MATERIAL AND METHODS
OSA cohort
All patients with moderate-to-severe OSA (apnoea
hypopnoea index (AHI)≥15 events/h) who were
referred to the Pulmonary Department, Landspitali—
The National University Hospital of Iceland for treat-
ment with PAP from September 2005 to December
2009, were invited to participate in the Icelandic Sleep
Apnea Cohort (ISAC) study,15–17 also referred to here-
after as the OSA cohort. No other inclusion or exclusion
criteria were used. Brieﬂy, over 90% of eligible and
approached patients agreed to participate in the study, a
total of 826 patients. Four patients withdrew from the
study, leaving 822 in the baseline cohort (666 men and
156 women). The patients in ISAC were also invited to a
2-year follow-up visit, performed in the same manner as
the initial visit. This follow-up was completed in 741
(90.1%) patients from October 2007 to January 2012.
General population cohort
The general population cohort was primarily invited to
participate in the Burden of Obstructive Lung Diseases
initiative in Iceland; a multicentre international study
aiming to estimate the burden of chronic obstructive
pulmonary disorder worldwide.18
The general population sample was a random sample
of Icelandic citizens, ≥40 years of age living in the capital
area of Reykjavik.15 19–21 At the end of November 2004, of
the 73 391 subjects ≥ 40 years of age living in the area,
939 subjects were randomly selected to participate (for
details, see ref. 19). Altogether, 762 of the 939 eligible
subjects (81.2%) responded. No signiﬁcant differences
were found with regard to age or smoking status between
responders and non-responders in this cohort. However,
there was a signiﬁcant difference in gender with propor-
tionally more men participating (p<0.01).
Questionnaires and measurements
The OSA patient cohort and the general population sub-
jects were evaluated at the outpatient clinic of the
Pulmonary Department, Landspitali—The National
University Hospital of Iceland. They answered the same
core questionnaire on general health status, current
smoking (smoking or tobacco use during the past month)
and whether they had hypertension and/or diabetes
(doctor diagnosis and medication), cardiovascular disease
(CVD) which was deﬁned as a doctor diagnosis of coronary
artery occlusion (myocardial infarction or heart attack),
heart failure and/or stroke. Participants in both studies
listed their medication use for hypertension and diabetes
(pharmacological treatment was coded according to the
Anatomical Therapeutic Chemical drug classiﬁcation
system http://www.whocc.no/atcddd), but participants in
ISAC also gave a detailed list of all other medications they
used. The Basic Nordic Sleep Questionnaire22 was adminis-
tered to all participants (includes questions on sleep
quality, insomnia symptoms, snoring, nocturnal sweating
and GER). The response alternatives for those questions
were on a frequency scale of 1–5: (1) never or very seldom,
(2) less than once a week, (3) once to twice a week, (4) 3–5
times a week and (5) every day or almost every day of the
week. Frequent nocturnal sweating was deﬁned as a score
of 4 or 5 for the following question “I perspire heavily
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during the night”, that is, reporting nocturnal sweating
≥3× week. Insomnia symptoms were deﬁned as difﬁculties
initiating sleep or maintaining sleep ≥3× week.15 Daytime
and nocturnal GER symptoms were deﬁned, respectively,
as reporting heartburn during the daytime and after going
to bed ≥1× week.23 24 Other questionnaires included the
Epworth Sleepiness Scale,25 a 12-item Short-Form Health
Survey (SF-12) for physical and mental quality of life26 and
questions on symptoms of restless legs syndrome (RLS)
based on recommendations from the International Restless
Legs Syndrome Study Group27 (same deﬁnition as in our
previous paper21). Additionally, we deﬁned subjects in the
general population as high or low risk for OSA based on
the Multivariable Apnea Prediction (MAP) index.28 The
MAP score is based on a self-reported frequency of occur-
rence of apnoea symptoms (snoring or gasping, breathing
stops, choking or struggling for breath during the night) as
well as body mass index (BMI), age and gender. The MAP
index ranges from 0 to 1 where subjects with a score of 0
are least likely to have OSA. A MAP index cut-off of 0.75
was used to deﬁne high risk OSA similar to our previous
publication.15 All questionnaires were translated from
English into Icelandic and back-translated to assure accur-
acy. Height and weight were measured in the same manner
for all participants. Participants were asked to remove their
shoes and heavy outer garments for the measurements.
The consent of the National Bioethics Committee and
the Data Protection Authority of Iceland as well as the
Institutional Review Board of the University of
Pennsylvania was granted for both studies and written
consent obtained from the research participants.
Sleep recording in ISAC cohort
Prior to referral for PAP treatment, all ISAC patients had
a type 3 sleep study with an Embletta type 3 portable
monitor, an Embla 12 channel system (Natus Medical
Inc, Ontario, Canada) or a T3 device (Nox Medical,
Reykjavik, Iceland). The same signals were recorded in
all studies. To test for systematic differences in the meas-
urement of OSA severity by Embletta versus T3,
13 patients slept with both devices simultaneously
during their laboratory diagnostic OSA study. Their AHI
ranged from 0 to 58 events/h. The intraclass correlation
coefﬁcient for AHI was 0.99 (p<0.001) and for oxygen
desaturation index (ODI) 0.97 (p<0.001) between the
devices, showing no signiﬁcant differences in the mea-
sured OSA severity.
All sleep studies were scored by trained sleep technol-
ogists based on the following criteria: studies had to
have ≥4 h of a scorable O2 saturation signal. A total of
15 sleep studies did not meet this criterion and were
excluded from all analysis of OSA severity. The apnoea–
hypopnoea index was calculated as the mean number of
apnoeas and hypopnoeas/h of recording (excluding
upright time). The ODI was calculated as the number of
drops in oxygen of ≥4%/h of recording (for a more
detailed methodology, see refs.16 and 17).
PAP use
All PAP treatments in Iceland are administered by the
Department of Respiratory Medicine and Sleep at
Landspitali—The National University Hospital of
Iceland, the sole provider of ventilator treatment in
Iceland. All patients with OSA were treated with autoPAP
or continuous PAP (CPAP) units (ResMed Corp., San
Diego, California, USA) and treatment was only changed
to bilevel PAP (BiPAP) or adaptive servoventilation if
treatment efﬁcacy on autoPAP or CPAP was inadequate
(deﬁned by AHI≥15 using PAP and/or persistent patient
complaints or based on clinical judgement). In those
patients on ResMed S8 machines, PAP adherence at
follow-up was objectively measured by downloading the
mask on-time stored by the PAP unit in the previous
4 weeks (available for 357 of 469 PAP users). Patients
recruited at the beginning of the study period had older
models of PAP devices which did not provide this type of
information. Self-report data from all patients were also
collected at the follow-up visit, based on three multiple-
choice questions about average PAP use: (1) Do you use
PAP for your sleep apnoea? (Yes, no or do not know), (2)
How many nights per week do you use PAP? (Response
alternatives: 1, 2, 3, 4, 5, 6 or 7 nights/week), (3) How
much of the sleeping time each night do you use PAP?
(Response alternatives: all the sleeping time (100%);
almost all the sleeping time (80–99%); most of the sleep-
ing time (60–79%); about half of the sleeping time (40–
59%); about one-third of the sleeping time (20–39%);
almost none of the sleeping time (1–19%); none of the
sleeping time (0%); do not know).
Statistical analysis
For bivariate analysis, the χ² and t tests were used for
nominal and continuous variables, respectively, whereas
logistic regression was used for multivariable analyses and
assessment of adjusted OR with 95% CI. The signiﬁcance
of change in the prevalence of symptoms with PAP treat-
ment was assessed using population-averaged generalised
estimating equations for a binomial outcome. The Wald
test was used to examine the differences in the change of
prevalence by the level of PAP use. A p value of ≤0.05 was
determined as statistically signiﬁcant. Means are given as
±SD unless otherwise indicated. STATA V.11.0 was used
for all statistical analyses. Statistical analysis using the ori-
ginal ﬁve-point scale for nocturnal sweating frequency
showed the same ﬁndings as using the binomial distribu-
tion for frequent sweating of ≥3× week (data not shown).
RESULTS
Characteristics of the study population
The characteristics of the study cohorts are shown in
table 1. The baseline OSA cohort included 822 patients,
n=666 men and n=156 women with an age range 21–
83 years. The general population cohort included in the
analysis was 703, of whom 374 were men and 329
women (see ﬁgure 1 for exclusion criteria).
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Patients in the OSA cohort had a higher BMI on
average than the general population subjects (see table 1),
but the range was similar (ISAC: 20.1–58.6 kg/m2, con-
trols: 20–55 kg/m2). Patients in the OSA cohort had a
higher prevalence of treated hypertension and diabetes
than subjects from the general population (table 1) and
reported more sleepiness on the Epworth Sleepiness
Scale. Additionally, men in the OSA cohort were 2 years
younger on average, more likely to be current smokers
and have a diagnosis of CVD than the men from the
general population. These differences were not found in
women.
Prevalence and characteristics of nocturnal sweating
Frequent nocturnal sweating (≥3 × a week) was reported
by 30.6% of men in the OSA cohort, while men in the
general population had a prevalence of 9.6%
(p<0.0001). A total of 33% of women in the OSA cohort
had frequent nocturnal sweating compared with 12.8%
of women in the general population (p<0.0001). Hence,
the OSA cohort had a threefold higher prevalence of
frequent nocturnal sweating than the general popula-
tion cohort (ﬁgure 2). Patients in the OSA cohort had a
higher prevalence of frequent nocturnal sweating within
all comparable gender and age groups (40–49, 50–59,
60–69 and ≥70 years) except in women ≥70 years, likely
due to power issues (n=20 OSA women and n=55
general population women; see ﬁgure 2). The distribu-
tion of sweating on the original ﬁve-point scale was also
much more skewed to the left in the general population
than in the untreated OSA cohort, where more subjects
report some degree of nocturnal sweating (see ﬁgure 3).
The demographic characteristics of subjects with and
without frequent nocturnal sweating are shown in table 2
Table 1 Characteristics of the males and females in the general population and OSA cohorts
Males Females
General
population (n=374)
OSA cohort
(n=666) p Value
General
population (n=329)
OSA cohort
(n=156) p Value
Age (years) 55.9±10.6 53.6±10.7 0.0008 56.9±11.6 58.4±9.1 0.16
BMI (kg/m2) 28.4±4.3 33.4±5.6 <0.0001 27.6±5.3 34.1±6.2 <0.0001
Epworth sleepiness scale 6.4±3.9 11.8±5.0 <0.0001 5.7±4.0 11.2±5.3 <0.0001
Current smokers (%) 15.6 21.6 0.02 20.7 19.2 0.71
Hypertension (%) 21.6 44.5 <0.0001 28.1 50.6 <0.0001
CVD (%) 14.7 20.0 0.03 14.0 11.6 0.47
Diabetes (%) 2.7 8.8 <0.0001 3.1 8.4 0.01
Significant findings (p<0.05) are shown in italics.
BMI, body mass index; CVD, cardiovascular disease, defined as a doctor diagnosis of coronary artery occlusion (myocardial infarction or
heart attack), heart failure and/or stroke. Hypertension and diabetes were defined as a doctor diagnosis and treatment with medication.
Figure 1 The study cohorts.
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(univariate analysis). Younger age was signiﬁcantly
related to nocturnal sweating among OSA patients
(p=0.003), but not in the general population (p=0.44).
Only in the general population cohort, subjects with
medically treated diabetes (n=20) were more likely to
report frequent nocturnal sweating (p<0.05). No rela-
tionship was found with gender, current smoking, diag-
nosed hypertension or CVD in either cohort in
unadjusted analyses (data not shown). However, those
reporting frequent nocturnal sweating reported lower
mental and physical quality of life, both the general
population and the OSA cohort (table 2).
To understand better which factors were associated
with frequent nocturnal sweating after adjustment for
other covariates, a multilogistic regression model was
created. OSA patients and general population subjects
were assessed separately. Variables tested in the model
were gender, age, BMI, current smoking, diagnosed
hypertension, CVD and diabetes. For both cohorts,
lower age was a signiﬁcant predictor of nocturnal sweat-
ing (see online supplementary Table S1). For the
general population subjects only, diagnosed CVD was an
additional signiﬁcant factor, and for the OSA cohort
only, hypertension was an additional signiﬁcant factor.
The effect of β-blockers and calcium-channel blockers
was tested speciﬁcally by multivariate analysis and was
not signiﬁcantly related to frequent nocturnal sweating
(data not shown). The role of antidepressants was tested
for the OSA cohort only (data not available in the
general population cohort). The use of antidepressants
was signiﬁcantly associated with frequent nocturnal
sweating, but did not change the signiﬁcance of other
ﬁndings within the OSA cohort.
When we combined both cohorts into one analysis
and adjusted for demographic factors, being a part of
the OSA cohort was still signiﬁcantly related to higher
prevalence of nocturnal sweating, with an OR of 3.11
(95% CI 2.25 to 4.30). No interaction with gender was
found for any of the tested demographic variables,
neither within the OSA cohort, general population
cohort or all subjects combined. Decreased mental and
physical quality of life remained signiﬁcantly lower in
those reporting frequent nocturnal sweating after adjust-
ment for demographic factors, both in the OSA and
general population cohorts (p<0.01).
Symptoms related to nocturnal sweating
Many sleep and respiratory symptoms were signiﬁcantly
related to nocturnal sweating in univariate analysis
(table 2). After adjustment for demographic factors, in
both the OSA cohort and the general population
cohort, nocturnal sweating was associated with insomnia
symptoms, excessive daytime sleepiness and RLS symp-
toms (see online supplementary Table S2). However,
only participants in the OSA cohort showed a
Figure 2 The prevalence of frequent nocturnal sweating (≥3× week) for subjects in the general population and the untreated
obstructive sleep apnoea (OSA) patient cohort, divided by gender and age groups. Significant differences (p<0.05) are shown by
an asterisk (*).
Figure 3 The distribution of reported nocturnal sweating (%)
on a 1–5 frequency scale for the general population and
untreated obstructive sleep apnoea (OSA) cohort.
Additionally, the full positive airway pressure (PAP) users at
the 2-year follow-up in the OSA cohort are shown. Subjects
with frequent nocturnal sweating were defined by a
prevalence ≥3× a week, as shown by the broken line.
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relationship between daytime and nocturnal GER and
nocturnal sweating. Subjects in the general population
reporting frequent nocturnal sweating were more likely
to report snoring. Also those with an increased risk of
OSA as calculated by the MAP score (n=46, 6.5%) were
borderline twice as likely to report frequent nocturnal
sweating (adjusted OR 2.08, 95% CI 0.94 to 4.59).
Fully adjusted models taking into account the effect
of other sleep and respiratory complaints were also
performed. Difﬁculty initiating sleep was most strongly
related to nocturnal sweating in the general popula-
tion (OR 4.05, 95% CI 1.72 to 9.54). For the OSA
patients, however, difﬁculties maintaining sleep,
daytime sleepiness and GER symptoms were most
strongly associated with frequent nocturnal sweating
(see online supplementary Table S2). Additional
adjustment for antidepressant use in the OSA cohort
did not affect the ﬁndings for the role of sleep or
respiratory complaints.
No association was found between frequent nocturnal
sweating and sleep apnoea severity in the OSA group on
continuous or categorical comparison with AHI and
ODI (categories: <20, 20–40, 40–60 and >60 events/h.).
Two year ISAC follow-up
A total of 741 (90.1%) participants in the OSA cohort
returned for a 2-year follow-up visit after starting PAP
treatment. No signiﬁcant differences were found in age,
BMI, OSA severity (as assessed by AHI or ODI) or
gender between non-responders (n=81) and responders
(n=741). At follow-up, ﬁve patients did not complete the
questions on nocturnal sweating, 33 patients were using
a mandibular advancement device instead of PAP and
3 had missing adherence data on PAP, leaving 700
patients in follow-up analysis of whom 469 were PAP
users and 231 non-users (ﬁgure 1).
PAP usage
At the 2-year follow-up, objective PAP data were available
for 357 of 469 PAP users (76.1%) with average (±SD) PAP
use per day for the last 4 weeks of 6.2 (±1.9) hours. Of
the PAP users, 53% were on autoPAP, 43% on CPAP, 3%
on BiPAP and 1% on adaptive servoventilation.
Participants with objective data, who used PAP for
≥20 days and ≥4 h/day on average for the previous
4 weeks, were considered full users (n=285 of 357 with
objective data). Full users used their device on average
26.7±2.0 days in the previous 4 weeks and 6.8±1.2 h/day.
Patients with objective PAP data who did not fulﬁl object-
ive criteria for full users were classiﬁed as partial users
(n=72). On average, partial users used their device for
14.5±7.1 days in the previous 4 weeks and 3.6±2.1 h/day
based on objective data. Non-users were deﬁned as those
who had returned their PAP device, had no objective use
in the last 4 weeks or reported no current use of PAP.
In those OSA patients for whom objective PAP data
were not available (n=112), the self-reported data were
used to deﬁne patients as full or partial PAP users. To
validate this approach, among the 355 patients with
both objective (memory cards) and self-reported data
on frequency of PAP use, we compared the cut-off for
objective full use (≥20 days and ≥4 h/day) versus partial
use to a comparable subjective cut-off for full use (≥5
nights/week and ≥60% of the sleeping time) versus
partial use. Self-report had 98.6% sensitivity and 45.1%
speciﬁcity in distinguishing full versus partial users.
Table 2 Characteristics of those reporting frequent nocturnal sweating (≥3× week) versus those reporting less frequent
sweating (≤2× week) in the general population and OSA cohorts
General population cohort OSA cohort
Frequent
sweating
(n=78)
Seldom
sweating
(n=625) p Value
Frequent
sweating
(n=256)
Seldom
sweating
(n=566) p Value
Age (years) 55.5±9.9 56.5±11.2 0.44 52.8±10.9 55.2±10.4 0.003
BMI (kg/m2) 28.9±4.8 27.9±4.8 0.09 34.0±4.9 33.3±6.0 0.08
Diabetes (%) 6.4 2.4 0.046 7.1 9.4 0.27
Physical quality of life (SF-12) 48.1±9.1 51.4±7.5 0.0004 37.6±10.4 41.5±10.8 <0.0001
Mental quality of life (SF-12) 49.9±5.5 51.6±4.6 0.003 45.9±11.8 49.4±10.3 <0.0001
Snoring ≥3 days/week (%) 39.0 24.6 0.02 98.0 94.2 0.02
Difficulties initiating sleep ≥3× week (%) 37.3 11.1 <0.0001 21.1 13.1 0.003
Difficulties maintaining sleep ≥3× week (%) 52.0 29.0 <0.0001 68.4 53.7 <0.0001
Epworth sleepiness scale 6.6±4.3 6.0±3.9 0.16 12.5±5.0 11.3±5.1 0.002
Feeling sleepy or drowsy 6–7× week (%) 16.7 7.2 0.004 78.8 60.1 <0.0001
Restless legs syndrome symptoms (%) 31.2 17.2 0.003 43.4 33.8 0.009
Nocturnal GER symptoms ≥1× week 9.0 5.5 0.22 21.9 10.5 <0.0001
Daytime GER symptoms ≥1× week 5.8 4.3 0.58 34.5 21.3 <0.0001
Significant findings (p<0.05) are shown in italics.
BMI, body mass index; GER, gastroesophageal reflux; OSA, obstructive sleep apnoea. Diabetes was defined as a doctor diagnosis and
treatment with medication.
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Primary data analysis did not exclude patients with
self-report PAP data only and patients on BiPAP or adap-
tive servoventilation (n=125). However, similar ﬁndings
were obtained when these patients were excluded from
follow-up analysis.
Non-users
Among the non-PAP users (n=231) in the OSA cohort,
56.7% (n=129) had a repeat sleep study when followed
after 2 years. On average, the AHI increased from 37.8
±15.0 events/h at baseline to 48.4±18.6 events/h at
follow-up, p<0.0001 and there was no weight change on
average. Altogether, 98% of the 129 patients still had AHI
≥15 events/h at the 2-year follow-up. A total of 17
non-users underwent upper airway surgery on the uvula
and/or soft palate between baseline and follow-up and 13
patients had >10% weight loss. Of these, 18 patients had
a repeat sleep study at follow-up. No signiﬁcant change
was found in their AHI between baseline and follow-up
on average and all patients still had AHI ≥15 despite
their alternative treatment for OSA. Primary data analysis
did not exclude these patients from the non-user group.
However, similar ﬁndings were obtained when these
patients were excluded from follow-up analysis (n=30).
Change in nocturnal sweating with treatment
The change in the prevalence of frequent nocturnal
sweating with PAP treatment in the OSA cohort was
tested by comparing full PAP users, partial PAP users
and non-users. A signiﬁcant decrease in the prevalence
of frequent nocturnal sweating was found in the full PAP
users as well as non-users at the 2-year follow-up
(p<0.001), but no signiﬁcant change was found in
partial PAP users. The full PAP users had a signiﬁcantly
greater decrease in frequent nocturnal sweating than
non-users (33.5% to 12% vs 31.6% to 20.4%, p=0.01;
table 3). A borderline signiﬁcant but small linear correl-
ation was found between decreased sweating at follow-up
and higher average daily use of PAP (r=−0.09, p=0.08)
in the 357 patients with objective data. Therefore, while
full PAP users were more likely to have a decrease in
nocturnal sweating than partial users, this effect was not
strongly linear.
The distribution of nocturnal sweating on the 1–5 fre-
quency scale for full PAP users was similar to the distri-
bution of the general population (ﬁgure 3). Non-users
and partial PAP users were also more likely than full PAP
users to report the continuation or development of
frequent sweating (≥3× week) at follow-up (p<0.01,
ﬁgure 4). However, frequent nocturnal sweating at base-
line did not predict whether a participant with OSA
became a full PAP user, partial PAP user or non-user as
all groups had similar prevalence of sweating at baseline.
Patients with decreased sweating had less development
and persistence of difﬁculties maintaining sleep ≥3×
week compared with those with persistent sweating. This
was found both for full PAP users and non-users (p<0.01
for both groups), but no difference was found for
Table 3 Frequent nocturnal sweating at 2-year follow-up for the different PAP adherence groups in the OSA cohort
Frequent nocturnal sweating
(≥3× week) Baseline (%) Follow-up (%) pchange
p compared with
non-PAP use
Non-users (n=231) 31.6 20.4 <0.001 –
Partial PAP users (n=102) 31.4 26.5 0.33 0.28
Full PAP users (n=367) 33.5 12.0 <0.001 0.01
Significant findings (p<0.05) are shown in italics.
OSA, obstructive sleep apnoea; PAP, positive airway pressure treatment.
Figure 4 The percentage of
obstructive sleep apnoea (OSA)
patients who reported no frequent
sweating (≥3× week) at both
baseline and follow-up, those who
developed sweating and had
persistent sweating between
baseline and follow-up, as well as
those with decreased sweating
(≤2× a week). The results are
shown separately for non-users,
partial positive airway pressure
(PAP) users and full PAP users.
The change in reported frequent
nocturnal sweating was
significantly different between the
three PAP groups (p<0.001).
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partial PAP users. Similarly, full PAP users that developed
frequent nocturnal sweating at follow-up had more difﬁ-
culties maintaining sleep (p=0.003) than patients with
no frequent sweating at both baseline and follow-up.
Only in non-users, patients with decreased sweating
also had decreased daytime sleepiness as assessed by the
Epworth Sleepiness Scale compared with those with per-
sistent frequent sweating (decrease by −3.5±4.4 vs,
−0.6±4.1 points, p=0.006). Also, full PAP users were
more likely to remain feeling sleepy/drowsy (p=0.003)
at follow-up if they developed frequent sweating, com-
paring to patients with no frequent sweating.
No signiﬁcant changes were found in reported difﬁcul-
ties initiating sleep, GER symptoms or RLS symptoms. No
signiﬁcant changes were found in mental or physical
quality of life for any of the PAP groups. No signiﬁcant
differences were found in the prevalence or change in
antidepressant use between full PAP users, partial users
or nonusers, indicating that this did not affect the
changes in nocturnal sweating found with PAP treatment.
DISCUSSION
The prevalence of frequent nocturnal sweating was
threefold higher in untreated OSA patients than in the
general population and decreased to general population
levels with successful PAP therapy. Nocturnal sweating
was more common among younger subjects. Subjects
with nocturnal sweating had an increased prevalence of
other sleep complaints, speciﬁcally, daytime sleepiness
and symptoms of insomnia. In the general population,
nocturnal sweating may be a marker of increased risk of
OSA as well as presence of insomnia.
The strengths of this study include the large number
of OSA patients studied and the comparison with a
general population cohort, as well as the extensive 2-year
follow-up of the ISAC cohort. This study included
detailed questionnaire assessments as well as anthropo-
metric measurements and sleep studies in all the OSA
patients. Our study was an observational study, not a ran-
domised controlled trial (RCT), which may be consid-
ered a limitation. However, an RCT study with such
long-term follow-up of untreated symptomatic OSA
patients would be difﬁcult to perform due to a lack of
clinical equipoise for PAP treatment. Other weaknesses
include the use of subjective measures of sweating. The
authors, however, recently conducted a study showing
that objective measurements of sweating (electrodermal
activity) during sleep in patients with OSA decreases
with PAP treatment, albeit in a smaller sample than that
reported here. Also, a signiﬁcant correlation was found
between reported frequency of nocturnal sweating by
the same questions and scale as we used in the present
study and the measured objective sweating in untreated
OSA patients (r=0.61, p=0.01).14 The OSA patients in
the current study were more obese and had a higher
prevalence of hypertension, CVD and diabetes than the
subjects from the general population. Therefore, we
adjusted for these comorbidities as covariates. Also, the
number of women was substantially lower in the OSA
cohort, a consequence of patients in Iceland in whom
OSA has been diagnosed and the lower prevalence of
OSA in women than men.29 30 However, no gender dif-
ferences were found in the prevalence of sweating and
no statistical interactions were found between gender
and the other tested variables related to nocturnal sweat-
ing (see online supplementary Tables S1 and S2). Also,
a sleep study was not performed in the general popula-
tion cohort. Therefore, we do not know how many sub-
jects in the general population cohort had treated or
untreated OSA and how much effect undiagnosed OSA
had on the prevalence of nocturnal sweating in the
general population. However, we assessed their OSA risk
by calculating their MAP index,28 a widely used and vali-
dated tool for OSA risk assessment.31 Finally, some
patients in the OSA cohort reported an improvement in
frequent nocturnal sweating despite receiving no PAP
treatment at follow-up. These patients also described less
sleepiness. This may be related to other life style
changes during the 2-year interim between baseline and
follow-up, demand characteristics, the Hawthorne effect
(improvement due to observation alone32) or regression
to the mean as most patients described severe symptoms
at baseline. Also, other treatment use may be a factor. We
did, however, remove all patients using a mandibular
advancement device from our follow-up analysis in the
OSA cohort and repeated the analyses excluding all
non-PAP users with signiﬁcant weight loss and upper
airway surgery (uvula/soft palate) between the baseline
and follow-up assessments, and this did not affect the
results. Finally, we would like to mention that heating in
Icelandic houses is relatively cheap and year-round
outdoor temperatures in Reykjavik rather low (monthly
average of −1°C to 11°C). Therefore, ambient tempera-
tures in houses should be stable across the year and
should not affect the current ﬁndings. Also, data collec-
tion was year-round, both for baseline and follow-up data.
Our study conﬁrms the ﬁndings of Cruz et al13 and
Kiely et al33 who showed a decrease of subjective sweating
with PAP treatment in smaller cohorts of OSA patients
(n=98 and 56, respectively). We have extended their
ﬁndings by showing that the prevalence in nocturnal
sweating in untreated OSA is three times larger than in
a general population cohort and that it is reduced to
general population levels with full PAP treatment. Also,
our ﬁndings show that partial PAP treatment is not sufﬁ-
cient to reduce nocturnal sweating. This relationship was
not strongly linear in nature, but rather required a
minimum of 4 h of usage and 5 days a week on average
similar to the Crawford et al34 study on the effects of
CPAP therapy on sleepiness. In the present study, we did
not ﬁnd a relationship between OSA severity and sub-
jective nocturnal sweating, in agreement with Mold
et al,10 but in disagreement with Cruz et al13 However,
most of the participants in our OSA cohort had
moderate-to-severe OSA, limiting our ability to assess
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relationships with OSA severity. The results of the
current study that nocturnal sweating is related to
daytime sleepiness are in agreement with Mold et al.10
Even in non-treated OSA patients, decreased complaints
of nocturnal sweating were related to decreased sleepi-
ness, possibly indicating a relationship with nocturnal
sweating beyond the presence of OSA per se. A possible
relationship may be found between nocturnal sweating
and decreased sleep quality as subjects reporting noctur-
nal sweating are sleepier and report poorer quality of
life in this study. In our earlier study, an association was
found between high objective sweating and low REM
sleep percentage in untreated OSA patients.14 However,
no association was found between objective sweating and
arousals or awakenings.14 Unlike the Mold et al study, we
did not ﬁnd a relationship with RLS symptoms.
However, they used a less strict deﬁnition of RLS than
we did. Interestingly, our ﬁndings are in agreement with
a study of a general cohort of children (n=6381) in
whom their parents reported more sleep-related sweat-
ing in relation to both OSA and insomnia symptoms.35
Nocturnal sweating has also previously been found to be
related to GER symptoms36 and younger age,13 as found
in this study. For the general population cohort, we
found indications that having OSA symptoms (both
snoring and higher MAP index) is related to reporting
frequent nocturnal sweating, unlike Mold et al10 in their
sleep laboratory sample. Our study also showed a rela-
tionship between decreased quality of life and frequent
nocturnal sweating, both in the general population and
OSA cohort, as has been shown previously in elderly
primary care patients.2 However, decreased sweating at
the follow-up of OSA patients was not related to any
improvement in quality of life. Similar to our earlier
study with objective measurements of sweating,14 we
found a possible relationship between reported sweating
and hypertension in OSA patients in this study.
Taken together, the results show that reported noctur-
nal sweating is common in patients with OSA and is
related to lower sleep quality and more daytime sleepi-
ness in this patient group. After successful PAP treat-
ment, the prevalence of nocturnal sweating decreases to
the same level as in the general population. Therefore,
clinicians should include OSA in the differential diagno-
sis of patients presenting with a complaint of nocturnal
sweating and further evaluate that possibility by perform-
ing a more complete sleep evaluation.
Future research that increases the understanding of
the link between OSA and nocturnal sweating is import-
ant. Studies assessing whether the subgroup of OSA
patients reporting nocturnal sweating have a different
risk proﬁle and/or different consequences such as
increased blood pressure would also be of interest.
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